cyclohexane;(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-3,4,10-trihydroxy-13-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one;hydrate

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: cyclohexane;(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-3,4,10-trihydroxy-13-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one;hydrate
• 化学式: C₆H₁₂*C₃₈H₇₂N₂O₁₂*H₂O
• 分子量: 851.172
• InChiKey: HFBFBVUIBINBOH-KUJJYQHYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.42
• 重原子数：
  59
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.98
• 拓扑面积：
  181
• 氢给体数：
  6
• 氢受体数：
  15

反应信息

• 作为反应物：
  描述：

  cyclohexane;(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-3,4,10-trihydroxy-13-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one;hydrate 80.0 ℃ 、2.0 kPa 条件下， 生成 阿奇霉素
  参考文献：
  名称：

  [EN] NOVEL AMORPHOUS 9-DEOXO-9A-AZA-9A-METHYL-9A-HOMOERYTHROMYCIN A, PROCESS FOR PREPARING THE SAME, AND USE THEREOF
  [FR] NOUVELLE 9-DEOXO-9A-AZA-9A-METHYL-9A-HOMOERYTHROMYCINE A AMORPHE, PROCEDES DE PREPARATION ET D'UTILISATION DE CETTE DERNIERE

  摘要：

  公开号：

  WO2004009608A3
• 作为产物：
  描述：

  环己烷 、 阿奇霉素 在 水 作用下， 生成 cyclohexane;(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-3,4,10-trihydroxy-13-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one;hydrate
  参考文献：
  名称：

  [EN] NOVEL AMORPHOUS 9-DEOXO-9A-AZA-9A-METHYL-9A-HOMOERYTHROMYCIN A, PROCESS FOR PREPARING THE SAME, AND USE THEREOF
  [FR] NOUVELLE 9-DEOXO-9A-AZA-9A-METHYL-9A-HOMOERYTHROMYCINE A AMORPHE, PROCEDES DE PREPARATION ET D'UTILISATION DE CETTE DERNIERE

  摘要：

  公开号：

  WO2004009608A3

文献信息

• Crystal forms of azithromycin
  申请人：——

  公开号：US20030162730A1

  公开（公告）日：2003-08-28

  The invention relates to novel crystal forms of azithromycin, an antibiotic useful in the treatment of infections.

  本发明涉及一种新型的阿奇霉素晶体形式，阿奇霉素是一种用于治疗感染的抗生素。
• New crystal form of Azithromycin
  申请人：Pfizer Products Inc.

  公开号：EP1652851A1

  公开（公告）日：2006-05-03

  The present invention relates to novel crystalline forms of azithromycin, an antibiotic useful in the treatment of infections. In particular, the invention relates to a crystalline form of azithromycin, wherein said form is substantially pure crystalline azithromycin monohydrate hemi-ethanol solvate.

  本发明涉及阿奇霉素的新型结晶形式，阿奇霉素是一种可用于治疗感染的抗生素。特别是，本发明涉及一种阿奇霉素的结晶形式，其中所述形式为基本纯净的阿奇霉素一水半乙醇溶液结晶。
• New Cristal Form of Azithromycin
  申请人：Pfizer Products Inc.

  公开号：EP1671979A1

  公开（公告）日：2006-06-21

  The present invention relates to novel crystalline forms of azithromycin, an antibiotic useful in the treatment of infections. In particular the invention relates to a crystalline form of azithromycin wherein said form is azithromycin monohydrate hemi-n-propanol solvate.

  本发明涉及阿奇霉素的新型结晶形式，阿奇霉素是一种可用于治疗感染的抗生素。本发明尤其涉及一种阿奇霉素的结晶形式，其中所述形式为阿奇霉素一水合物半正丙醇溶液。
• Methods for wet granulating azithromycin
  申请人：Pfizer Inc.

  公开号：US20030190365A1

  公开（公告）日：2003-10-09

  The present invention relates to a method of forming non-dihydrate azithromycin granules, comprising mixing non-dihydrate azithromycin particles, with a granulating amount of a granulating liquid, and, optionally, with one or more excipients, to form wet granules which comprise non-dihydrate azithromycin and the granulating liquid. The granules are then dried to remove the granulating liquid. The invention further relates to a pharmaceutical composition comprising granules of a non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. The invention also relates to pharmaceutical formulations comprising granules of non-dihydrate azithromycin. The invention further relates to granules of dihydrate azithromycin wherein the granules comprises 98-100% dihydrate azithromycin and from about 0-2%, total weight, of one or more pharmaceutically acceptable excipients.

  本发明涉及一种形成非二水阿奇霉素颗粒的方法，包括将非二水阿奇霉素颗粒与造粒量的造粒液混合，还可选择与一种或多种赋形剂混合，以形成包含非二水阿奇霉素和造粒液的湿颗粒。然后将颗粒干燥，除去制粒液。 本发明还涉及一种药物组合物，它包括非二水阿奇霉素颗粒和至少一种药学上可接受的赋形剂。 本发明还涉及包含非二水阿奇霉素颗粒的药物制剂。 本发明进一步涉及二水合阿奇霉素颗粒剂，其中颗粒剂包含 98-100% 的二水合阿奇霉素和约 0-2% 的一种或多种药学上可接受的赋形剂（总重量）。
• Dry granulated formulations of azithromycin
  申请人：Pfizer Inc.

  公开号：US20030228357A1

  公开（公告）日：2003-12-11

  This invention relates to a pharmaceutical formulation, in the form of a tablet, sachet or powder for suspension dosage form, which comprises dry granulated particles of a non-dihydrate form of azithromycin and, optionally, one or more pharmaceutically acceptable excipients. Preferably, the pharmaceutical formulation is a tablet containing between about 40%, by weight, to about 90%, by weight, non-dihydrate azithromycin. More preferably, the pharmaceutical formulation contains non-dihydrate azithromycin selected from the forms B, D, E, F, G, H, J, M, N, O, P, Q, R, or mixtures thereof. Even more preferably, the invention relates to a pharmaceutical formulation wherein the dosage of azithromycin is 250 mgA, 500 mgA, 600 mgA or 1000 mgA. The present invention further relates to a dry granulated azithromycin particle, comprising a form of azithromycin, selected from forms D, E, F, G, H, J, M, N, O, P, Q, R and mixtures of non-dihydrate forms, and at least one pharmaceutically acceptable excipient.

  本发明涉及一种药物制剂，其剂型为片剂、小袋装或粉末悬浮剂，包括非二水阿奇霉素的干颗粒，以及一种或多种药学上可接受的赋形剂。优选地，药物制剂是一种片剂，含有约 40%（按重量计）至约 90%（按重量计）的非二水合物阿奇霉素。 更优选地，药物制剂含有选自 B、D、E、F、G、H、J、M、N、O、P、Q、R 或其混合物的非二水阿奇霉素。 更优选地，本发明涉及一种药物制剂，其中阿奇霉素的剂量为 250 mgA、500 mgA、600 mgA 或 1000 mgA。 本发明进一步涉及一种干颗粒阿奇霉素颗粒，它包含一种阿奇霉素形式，选自形式D、E、F、G、H、J、M、N、O、P、Q、R和非二水合物形式的混合物，以及至少一种药学上可接受的赋形剂。